Payment overview · 2025
General Payments
$150.47
6 reported records · 4 companies
Healthcare provider profile · identity verified
Michelle Cheloha, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SCOTTSBLUFF, NE · NPI 1083637409
Verified facts
What the public records show
CMS Open Payments records show Michelle Cheloha, M.D. received $150.47 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 49.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Vraylar by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.36 | 49.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.03 | 22.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.49 | 18.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.59 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.47 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.18 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
98 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
188 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 762 | 132 |
| Gabapentin | Gabapentin | 537 | 94 |
| Omeprazole | Omeprazole | 451 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 447 | 92 |
| Lisinopril | Lisinopril | 355 | 74 |
| Losartan Potassium | Losartan Potassium | 342 | 70 |
| Meloxicam | Meloxicam | 302 | 75 |
| Tramadol Hcl | Tramadol Hcl | 298 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 296 | 51 |
| Simvastatin | Simvastatin | 285 | 56 |
| Montelukast Sodium | Montelukast Sodium | 280 | 62 |
| Furosemide | Furosemide | 270 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 232 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 228 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 42 |
| Metformin Hcl | Metformin Hcl | 221 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 47 |
| Warfarin Sodium | Warfarin Sodium | 217 | 85 |
| Oxycodone Hcl | Oxycodone Hcl | 204 | 29 |
| Eliquis | Apixaban | 188 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 38 |
| Potassium Chloride | Potassium Chloride | 183 | 35 |
| Trazodone Hcl | Trazodone Hcl | 178 | 37 |
| Memantine Hcl | Memantine Hcl | 172 | 28 |
| Methylprednisolone | Methylprednisolone | 172 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 166 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 35 |
| Donepezil Hcl | Donepezil Hcl | 139 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 133 | 26 |
| Sertraline Hcl | Sertraline Hcl | 127 | 20 |
| Spironolactone | Spironolactone | 126 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 124 | 23 |
| Lorazepam | Lorazepam | 123 | 37 |
| Azithromycin | Azithromycin | 117 | 77 |
| Bupropion Xl | Bupropion Hcl | 117 | 19 |
| Fentanyl | Fentanyl | 112 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 26 |
| Ozempic | Semaglutide | 108 | 17 |
| Glipizide | Glipizide | 107 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 37 |
| Alendronate Sodium | Alendronate Sodium | 104 | 26 |
| Carvedilol | Carvedilol | 102 | 21 |
| Clonidine Hcl | Clonidine Hcl | 102 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 21 |
| Pregabalin | Pregabalin | 99 | 23 |
| Linzess | Linaclotide | 98 | 17 |
| Buspirone Hcl | Buspirone Hcl | 95 | 18 |
| Topiramate | Topiramate | 89 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 34 |
| Bumetanide | Bumetanide | 86 | 15 |
| Metformin Hcl Er | Metformin Hcl | 82 | 24 |
| Mounjaro | Tirzepatide | 82 | 13 |
| Sucralfate | Sucralfate | 82 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 17 |
| Alprazolam | Alprazolam | 79 | 15 |
| Aripiprazole | Aripiprazole | 78 | suppressed |
| Cephalexin | Cephalexin | 72 | 49 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 13 |
| Allopurinol | Allopurinol | 70 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 68 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 18 |
| Estradiol | Estradiol | 67 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 40 |
| Amoxicillin | Amoxicillin | 61 | 40 |
| Diazepam | Diazepam | 61 | suppressed |
| Myrbetriq | Mirabegron | 59 | suppressed |
| Levofloxacin | Levofloxacin | 58 | 39 |
| Vraylar | Cariprazine Hcl | 55 | suppressed |
| Lamotrigine | Lamotrigine | 54 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 27 |
| Fluconazole | Fluconazole | 53 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 12 |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 14 |
| Prednisone | Prednisone | 47 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 46 | 46 |
| Meclizine Hcl | Meclizine Hcl | 45 | 11 |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Celecoxib | Celecoxib | 39 | 12 |
| Famotidine | Famotidine | 39 | suppressed |
| Glyburide | Glyburide | 39 | suppressed |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 24 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Nabumetone | Nabumetone | 33 | suppressed |
| Naproxen | Naproxen | 33 | 11 |
| Finasteride | Finasteride | 32 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 32 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Nystatin | Nystatin | 27 | 16 |
| Cefdinir | Cefdinir | 26 | 21 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Premarin | Estrogens, Conjugated | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 22 |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Xtampza Er | Oxycodone Myristate | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Pimozide | Pimozide | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Cholestyramine Light | Cholestyramine | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 18 | suppressed |
| Armodafinil | Armodafinil | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Peg 3350-Electrolyte | Sodium Chloride/Nahco3/Kcl/Peg | 13 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Rinvoq | Upadacitinib | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.47 · 6 records | ABBVIE INC. | NURTEC ODT, Ozempic, QULIPTA, REXULTI, UBRELVY, VRAYLAR, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error